Published in J Virol on February 01, 2005
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
Quasispecies theory and the behavior of RNA viruses. PLoS Pathog (2010) 3.19
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. J Infect Dis (2015) 2.52
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A (2008) 1.83
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol (2006) 1.75
Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol (2015) 1.73
Extremely High Mutation Rate of HIV-1 In Vivo. PLoS Biol (2015) 1.72
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis (2014) 1.56
Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol (2008) 1.53
Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med (2016) 1.48
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol (2007) 1.47
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS One (2010) 1.46
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol (2008) 1.36
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem (2010) 1.36
Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol (2008) 1.33
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol (2010) 1.22
Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol (2009) 1.19
T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog (2007) 1.19
Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. J Virol (2014) 1.18
HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS (2013) 1.15
Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS (2008) 1.09
The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med (2009) 1.07
Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05
Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog (2011) 1.05
Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol (2010) 1.04
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet (2014) 1.00
Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy. J Virol (2015) 0.98
APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol (2013) 0.97
APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology (2012) 0.97
Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J Biol Chem (2010) 0.97
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet (2012) 0.95
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Powerful mutators lurking in the genome. Philos Trans R Soc Lond B Biol Sci (2009) 0.92
Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PLoS One (2011) 0.91
Drug resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural Malawi. AIDS Res Hum Retroviruses (2010) 0.91
Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy. J Virol (2010) 0.90
Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. J Virol (2014) 0.89
Subtype-associated differences in HIV-1 reverse transcription affect the viral replication. Retrovirology (2010) 0.89
APOBEC3 Proteins in Viral Immunity. J Immunol (2015) 0.89
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87
Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology (2012) 0.87
AID and APOBECs span the gap between innate and adaptive immunity. Front Microbiol (2014) 0.87
APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome. Retrovirology (2012) 0.86
Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses (2012) 0.85
HIV drug resistance mutations in proviral DNA from a community treatment program. PLoS One (2015) 0.84
APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans. Mol Biol Int (2012) 0.84
The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence. J Immunol (2016) 0.82
HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. J Virol (2016) 0.82
In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins. Virology (2011) 0.81
Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals. J Int AIDS Soc (2013) 0.81
Molecular evolution of HIV-1 CRF01_AE Env in Thai patients. PLoS One (2011) 0.81
Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation. PLoS Pathog (2016) 0.80
Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections. J Virol (2014) 0.79
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. Antimicrob Agents Chemother (2015) 0.79
Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers. J Virol (2015) 0.79
Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition. Bioinformation (2014) 0.79
No evidence of xenotropic murine leukemia virus-related virus transmission by blood transfusion from infected rhesus macaques. J Virol (2012) 0.78
Effects of Korean Red Ginseng and HAART on vif Gene in 10 Long-Term Slow Progressors over 20 Years: High Frequency of Deletions and G-to-A Hypermutation. Evid Based Complement Alternat Med (2013) 0.78
Establishment and stability of the latent HIV-1 DNA reservoir. Elife (2016) 0.78
Evolution of the long terminal repeat and accessory genes of feline immunodeficiency virus genomes from naturally infected cougars. Virology (2007) 0.76
Retroviral vectors for analysis of viral mutagenesis and recombination. Viruses (2014) 0.76
APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Res (2016) 0.76
Mechanism of enhanced HIV restriction by virion coencapsidated cytidine deaminases APOBEC3F and APOBEC3G. J Virol (2016) 0.76
Inducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds. Antimicrob Agents Chemother (2009) 0.76
HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity. Retrovirology (2014) 0.76
Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation. J Clin Microbiol (2016) 0.75
GANP interacts with APOBEC3G and facilitates its encapsidation into the virions to reduce HIV-1 infectivity. J Immunol (2013) 0.75
In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients. AIDS Res Hum Retroviruses (2014) 0.75
APOBEC3G-Mediated G-to-A Hypermutation of the HIV-1 Genome: The Missing Link in Antiviral Molecular Mechanisms. Front Microbiol (2016) 0.75
Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy. Virol J (2016) 0.75
Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra. J Mol Biol (2017) 0.75
The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol (1987) 266.90
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes. J Virol (1991) 5.03
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A (2004) 3.73
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol (2004) 3.59
HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA (2001) 3.41
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Detecting hypermutations in viral sequences with an emphasis on G --> A hypermutation. Bioinformatics (2000) 3.07
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
A new type of G-->A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses (1993) 2.19
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest (2000) 1.81
Death by deamination: a novel host restriction system for HIV-1. Cell (2003) 1.71
A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G-->A hypermutation during negative-strand viral DNA synthesis. Virology (1995) 1.38
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28
The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med (2007) 3.20
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol (2005) 2.99
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol (2007) 2.71
The multifactorial nature of HIV-1 latency. Trends Mol Med (2004) 2.68
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol (2005) 2.55
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology (2012) 2.29
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol (2009) 2.10
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe (2008) 2.08
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog (2006) 2.08
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis (2006) 2.06
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog (2013) 2.02
Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis (2007) 1.96
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis (2009) 1.93
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol (2008) 1.91
Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89
Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol (2009) 1.89
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88
A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother (2004) 1.87
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85
Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol (2003) 1.83
The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem (2008) 1.83
Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol (2008) 1.82
Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog (2007) 1.81
Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol (2007) 1.77
A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis (2008) 1.76
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest (2015) 1.76
S-nitrosylation of N-ethylmaleimide sensitive factor mediates surface expression of AMPA receptors. Neuron (2005) 1.73
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A (2008) 1.72
Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis (2010) 1.70
A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med (2012) 1.68
Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66
Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66
Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol (2004) 1.64
The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS (2008) 1.63
HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother (2006) 1.63
Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.63
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest (2013) 1.62
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med (2012) 1.61
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS (2008) 1.50
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods (2006) 1.49
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol (2007) 1.47
Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol (2007) 1.47
A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis (2013) 1.46
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis (2010) 1.45